Document Detail

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.
MedLine Citation:
PMID:  22177848     Owner:  NLM     Status:  Publisher    
In a phase I/IIa clinical trial, 17 HIV-1 infected patients, stable on cART, received 4 vaccinations with autologous dendritic cells electroporated with mRNA encoding Tat, Rev and Nef, after which cART was interrupted. Vaccination was safe and feasible. During the analytical treatment interruption (ATI), no serious adverse events were observed. Ninety-six weeks following ATI, 6/17 patients remained off therapy. Although induced and/or enhanced CD4(+) and CD8(+) T-cell responses specific for the immunogens were observed in most of the patients, we found no correlation with the number of weeks off cART. Moreover, CD4(+) T-cell counts, plasma viral load and the time remaining off cART following ATI did not differ from historical control data. To conclude, the vaccine was safe, well tolerated and resulted in vaccine-specific immune responses. Since no correlation with clinical parameters could be found, these results warrant further research in order to optimize the efficacy of vaccine-induced T-cell responses.
Sabine D Allard; Brenda De Keersmaecker; Anna L de Goede; Esther J Verschuren; Jeanette Koetsveld; Mariska L Reedijk; Carolien Wylock; Annelies V De Bel; Judith Vandeloo; Frank Pistoor; Carlo Heirman; Walter E P Beyer; Paul H C Eilers; Jurgen Corthals; Iman Padmos; Kris Thielemans; Albert D M E Osterhaus; Patrick Lacor; Marchina E van der Ende; Joeri L Aerts; Carel A van Baalen; Rob A Gruters
Related Documents :
12516058 - The new cell culture smallpox vaccine should be offered to the general population.
2124208 - Anterior neopharyngeal diverticulum following laryngectomy.
16796628 - Smallpox vaccination site complications.
238178 - Smallpox vaccination reactions, prophylaxis, and therapy of complications.
21283048 - Second-dose varicella vaccination coverage in children and adolescents in a managed car...
16151038 - Rifapentine, moxifloxacin, or dna vaccine improves treatment of latent tuberculosis in ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-16
Journal Detail:
Title:  Clinical immunology (Orlando, Fla.)     Volume:  -     ISSN:  1521-7035     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-12-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883537     Medline TA:  Clin Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Department of Internal Medicine and Infectious Diseases, Universitair Ziekenhuis Brussel, Brussels, Belgium; Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiat...
Next Document:  Rising preterm birth rates, 1989-2004: changing demographics or changing obstetric practice?